Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JS201
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Shanghai Junshi Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JS201 is a bifunctional fusion protein developed by Junshi using its proprietary technology that can simultaneously target PD-1 and TGF-β (transforming growth factor-β). First product targeting PD-1/TGF-β approved for a clinical trial application in C...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 03, 2021
Lead Product(s) : JS201
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Shanghai Junshi Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Recipient : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Innovent Biologics has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which targets the COVID-19 virus, an independently-developed project by Innovent.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Recipient : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
